^
BIOMARKER:

MSI-H/dMMR

i
Other names: MSI-H, Microsatellite instability - high, dMMR
Related biomarkers:
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
J Clin Oncol - 5 days
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: C3 – Early Trials
BMC Cancer - 1 week
MSI-H/dMMR
Gastric Cancer
FLOT
Sensitive: C3 – Early Trials
BMC Cancer - 1 week
MSI-H/dMMR
Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
Clin Nucl Med - 2 weeks
MSI-H/dMMR
Biliary Tract Cancer
dostarlimab
Sensitive: A2 - Guideline
NCCN - 3 weeks
MSI-H/dMMR
HCC
dostarlimab
Sensitive: A2 - Guideline
NCCN - 3 weeks
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab
Sensitive: A1 - Approval
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
CRC
dostarlimab
Sensitive: A2 - Guideline
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Fallopian Tube Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Maxillary Sinus Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
CRC
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Testicular Cancer
cemiplimab
Sensitive: A2 - Guideline
MSI-H/dMMR
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Solid Tumor
KN035
Sensitive: B - Late Trials
MSI-H/dMMR
CRC
KN035
Sensitive: B - Late Trials
MSI-H/dMMR
Gastric Cancer
KN035
Sensitive: B - Late Trials
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
MSI-H/dMMR
Solid Tumor
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
RCC
dostarlimab
Sensitive: C1 - Off-label
MSI-H/dMMR
Gallbladder Cancer
dostarlimab
Resistant: C1 - Off-label
MSI-H/dMMR
Esophageal Cancer
dostarlimab
Resistant: C1 - Off-label
MSI-H/dMMR
Breast Cancer
dostarlimab
Sensitive: C1 - Off-label
MSI-H/dMMR
Ovarian Cancer
dostarlimab
Sensitive: C1 - Off-label
MSI-H/dMMR
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Uterine Cancer
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Gastric Cancer
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Gallbladder Cancer
pembrolizumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Prostate Cancer
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Cervical Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
MSI-H/dMMR
GBM
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Gastrointestinal Cancer
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Gastrointestinal Cancer
pembrolizumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Urothelial Cancer
nivolumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Urothelial Cancer
pembrolizumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Endometrial Cancer
INCMGA0012
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
durvalumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Endometrial Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
CRC
regorafenib
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
CRC
XmAb717
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
CRC
avelumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Gastric Cancer
CP-675206
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Gastric Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
avelumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
tislelizumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
BMS-986016
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Gastric Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Rectal Cancer
sintilimab
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
HX008
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
Solid Tumor
HLX10
Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR
CRC
Immunotherapy
Sensitive: C3 – Early Trials
MSI-H/dMMR
Solid Tumor
M7824
Resistant: C3 – Early Trials
MSI-H/dMMR
CRC
bevacizumab
Resistant: C3 – Early Trials
MSI-H/dMMR
Endometrial Adenocarcinoma
AZD1775
Sensitive: C3 – Early Trials
MSI-H/dMMR
Prostate Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
CRC
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
MSI-H/dMMR
Prostate Cancer
paclitaxel + docetaxel + etoposide IV
Sensitive: C3 – Early Trials
MSI-H/dMMR
Biliary Tract Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
Solid Tumor
camrelizumab
Sensitive: C3 – Early Trials
MSI-H/dMMR
Gastric Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
CRC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
Gastric Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
MSI-H/dMMR
Prostate Cancer
pembrolizumab + BBI608
Sensitive: C3 – Early Trials
MSI-H/dMMR
Prostate Cancer
pembrolizumab + enzalutamide
Sensitive: C3 – Early Trials
MSI-H/dMMR
CRC
nivolumab + TAS-116
Sensitive: C3 – Early Trials
MSI-H/dMMR
CRC
pembrolizumab + maraviroc
Sensitive: C3 – Early Trials
MSI-H/dMMR
Urothelial Cancer
atezolizumab
Sensitive: C3 – Early Trials
MSI-H/dMMR
Endometrial Cancer
nivolumab + cabozantinib tablet
Sensitive: C3 – Early Trials
MSI-H/dMMR
Gastric Cancer
sintilimab
Sensitive: C3 – Early Trials
MSI-H/dMMR
CRC
camrelizumab + SHR7390
Sensitive: C3 – Early Trials